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Abstract 27 
 28 
Phenotypic screens for bactericidal compounds are starting to yield promising 29 
hits against tuberculosis. In this regard, whole genome sequencing of 30 
spontaneous resistant mutants generated against an indazole sulfonamide 31 
(GSK3011724A) identifies several specific single nucleotide polymorphisms in 32 
the essential Mycobacterium tuberculosis β-ketoacyl synthase (kas) A gene. Here, 33 
this genomic-based target assignment is confirmed by biochemical assays, 34 
chemical proteomics and structural resolution of a KasA-GSK3011724A 35 
complex by X-ray crystallography. Finally, M. tuberculosis GSK3011724A-36 
resistant mutants increase the in vitro minimum inhibitory concentration and the 37 
in vivo 99% effective-dose in mice, establishing in vitro and in vivo target 38 
engagement. Surprisingly, the lack of target engagement of the related β-39 
ketoacyl synthases (FabH and KasB) suggests a different mode of inhibition 40 
when compared with other Kas inhibitors of fatty acid biosynthesis in bacteria. 41 
These results clearly identify KasA as the biological target of GSK3011724A and 42 
validate this enzyme for further drug discovery efforts against tuberculosis. 43 
 44 
  45 
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Introduction 46 
 47 
After many years of relatively little attention, Mycobacterium tuberculosis, the 48 
causative agent of tuberculosis (TB), has re-emerged as a priority in the area of 49 
neglected diseases1. The standard six-month treatment for TB has remained 50 
essentially unchanged over several decades2. Unfortunately, poor patient compliance 51 
and other factors have led to an increasing prevalence of drug resistance. In 2013, the 52 
World Health Organization (WHO) recorded approximately 480,000 new cases of 53 
multi-drug resistant (MDR)-TB, resistant to both the front-line drugs, isoniazid (INH) 54 
and rifampicin (RIF)3. Without these two front-line drugs, MDR-TB generally 55 
requires twenty-four months of treatment with a variety of second-line antibiotics, 56 
which are poorly tolerated. Due to this continued spread of MDR and extensively-57 
drug resistant (XDR) forms of M. tuberculosis, the WHO has declared TB as a world 58 
health emergency3. Therefore, new drugs that can complement existing front-line 59 
treatment regimens are urgently required. 60 
 61 
In 2013 and updated in 2015, GlaxoSmithKline published a set of 228 small molecule 62 
hits from two phenotypic screening campaigns against M. tuberculosis4,5. Of those 63 
228 compounds, a number have been explored via medicinal chemistry for potential 64 
optimisation to drug leads and clinical candidates. Phenotypic screening also offers 65 
the opportunity to identify novel biological targets by molecular mode of action 66 
(MoA) studies, which is generally achieved through a variety of omics-based 67 
technologies6-10. GSK3011724A is a small molecule inhibitor from the 68 
aforementioned 228 phenotypic screening hits4,5.  In this study, we provide an initial 69 
profiling of GSK3011724A as a suitable starting point for ‘hit’ to ‘lead’ drug 70 
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development based on its in vitro and in vivo characteristics. Additionally, through 71 
MoA studies, we identify the M. tuberculosis cellular target of GSK3011724A to be 72 
KasA, a β-ketoacyl synthase. Target assignment reveals specificity of GSK3011724A 73 
for KasA with a binding site distinct from other known Kas inhibitors. This different 74 
MoA creates new potential for this recognised target in future TB drug discovery 75 
efforts.   76 
 77 
Results 78 
 79 
In vitro profiling of GSK3011724A 80 
 81 
From the outset, GSK3011724A, an indazole sulfonamide (Fig. 1a), represented an 82 
attractive compound for early stage drug discovery based on its anti-mycobacterial 83 
potency, small size and moderate lipophilicity (Table 1). Further profiling in vitro 84 
using standard assays, such as the hERG ion channel and cytochrome P450 isoforms 85 
supported this view (Table 1). Sensitivity testing of 18 Gram-positive and Gram-86 
negative bacterial species with GSK3011724A demonstrated selectivity of this 87 
compound for M. tuberculosis. Additionally, GSK3011724A showed negligible 88 
activity against a panel of unrelated proteins (Supplementary Table 1). These 89 
desirable characteristics demonstrated the clear potential of GSK3011724A as a 90 
starting point for medicinal chemistry optimisation. A description of this optimisation 91 
effort along with a thorough discussion of the drug development potential and 92 
liabilities of this series will be the subject of a future publication. 93 
 94 
In vivo profiling of GSK3011724A 95 
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 96 
GSK3011724A was progressed into pharmacokinetic (PK) and efficacy experiments 97 
to generate an in vivo profile. Although doses above 400 mg.kg-1 were not well 98 
tolerated by mice, multiple days of dosing up to 300 mg.kg-1 once daily proceeded 99 
with no weight loss or other adverse effects. The in vivo PK of GSK3011724A in 100 
mice was disproportional based on dosing. At low doses, clearance close to the liver 101 
blood flow rate was observed (in agreement with the in vitro clearance (Cli) in mouse 102 
microsomes), but as the doses were increased, the maximum concentration (Cmax) 103 
and area under the curve (AUC) values grew disproportionally (Table 2). This 104 
observation suggests a saturation of the mechanism of clearance, and may help to 105 
explain the reduction in tolerability between 300 and 400 mg.kg-1 dosing. 106 
 107 
The first stage of efficacy testing involved an acute model of infection11. This murine 108 
model involved infecting mice with a high inoculum (105 colony forming units 109 
(CFU)) of M. tuberculosis H37Rv wild-type and beginning treatment the next day. 110 
GSK3011724A (and INH as a positive control) were administered once daily for 8 111 
days, while the bacilli were in the exponential growth phase. Despite exhibiting a 112 
bacteriostatic effect in vitro (Supplementary Fig. 1), GSK3011724A demonstrated a 113 
significant cidal effect in this murine model with an approximate 3.5 log CFU 114 
reduction relative to untreated controls at 200 mg.kg-1 (Fig. 1b). The effects of 115 
GSK3011724A are similar to linezolid, which has been shown to be bacteriostatic in 116 
vitro12, but exhibits cidality in vivo11.  Importantly, a clear dose response was 117 
observed, with the ED99 (dose required to reduce bacterial load by 99 %) determined 118 
as 38 mg.kg-1. This level of ED99 is only moderately higher than most of the gold 119 
standard TB drugs11.  120 
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 121 
GSK3011724A (and INH as a positive control) was also evaluated in a chronic 122 
infection assay in which mice were infected with a lower inoculum of M. tuberculosis 123 
H37Rv (102 CFU) and left untreated for 6 weeks, allowing the bacilli to reach a 124 
steady state. GSK3011724A was then dosed daily for two months. The dose response 125 
curve in this chronic assay was shifted to higher doses than in the acute model, but the 126 
targeted >2 log CFU reduction was achieved at 100 mg.kg-1 for GSK3011724A, 127 
producing a 2.4 log CFU reduction (Fig. 1c). These data clearly establish 128 
GSK3011724A as an active compound in both the acute and chronic in vivo murine 129 
models of M. tuberculosis infection. Importantly, if GSK3011724A were 130 
demonstrated to inhibit an unexploited potential antimicrobial target, these data would 131 
provide a significant level of validation and confidence for further exploration of that 132 
target for TB drug discovery. 133 
 134 
GSK3011724A target identification 135 
 136 
A fundamental strategy in drug discovery is establishing the MoA of inhibitory 137 
compounds. Following the identification and validation of the molecular target, 138 
target-specific optimisation of the compound can be pursued in order to improve 139 
efficacy and reduce toxicity. Due to the recent successes of utilising whole genome 140 
sequencing (WGS) of spontaneous resistant mutants as a primary step in the 141 
elucidation of the target of phenotypic hits6,7,9, this methodology was used to establish 142 
the target of GSK3011724A. 143 
 144 
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The minimum inhibitory concentration (MIC) of GSK3011724A in Mycobacterium 145 
bovis BCG was determined to be 0.5 µM. Spontaneous resistant mutants were initially 146 
generated using M. bovis BCG at 5 x, 10 x and 20 x the MIC of GSK3011724A, with 147 
frequencies of resistance (FoR) of 12 x 10-8, 3 x 10-8 and 2 x 10-8, respectively. The 148 
FoR was subsequently determined against M. tuberculosis at 2.5 µM (10 x MIC of 149 
GSK3011724A on solid media, 0.25 µM) giving a frequency of 9.5 x 10-7. This FoR 150 
is slightly higher than normally desired but is lower than that of INH.  151 
 152 
From the total of seventeen M. bovis BCG spontaneous resistant mutants generated, 153 
eight were selected for WGS. Six of the eight M. bovis BCG mutants were found to 154 
possess a number of high-quality (statistically relevant) single nucleotide 155 
polymorphisms (SNP) compared to the sequenced wild-type reference strain 156 
(Genbank accession number NC_008769.1), all of which located to the gene 157 
annotated kasA, encoding an essential β-ketoacyl synthase involved in mycolic acid 158 
biosynthesis13 (Table 3). The data offered the first evidence that KasA is the target of 159 
GSK3011724A, providing a starting point for validation studies. Subsequently, 160 
instead of using WGS, the kasA gene from twelve isolated M. tuberculosis resistant 161 
mutants was specifically sequenced following amplification by PCR. The data 162 
confirmed the results from M. bovis BCG, with eleven of the twelve mutants showing 163 
SNPs in kasA (Table 3). The WGS results of the two remaining M. bovis BCG 164 
mutants did not reveal SNPs of a high frequency; no gene contained a SNP of greater 165 
than 50 % frequency, corresponding to the percentage of SNP in the cell population 166 
from which the genomic DNA was prepared. 167 
 168 
KasA target validation 169 
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 170 
Following the target identification of KasA by WGS, a variety of techniques were 171 
utilised to confirm its role as the biological target of GSK3011724A. Firstly, the 172 
inhibition of mycolic acid biosynthesis by GSK3011724A was investigated. M. bovis 173 
BCG was labelled using [14C]-acetate and treated with increasing concentrations of 174 
GSK3011724A, with INH and the KasA inhibitor thiolactomycin (TLM) used as 175 
positive controls. Following drug treatment, the total fatty acid methyl esters 176 
(FAMEs) and α-mycolate and keto-mycolic acid methyl esters (α- and k-MAMEs) 177 
were extracted and analysed by autoradiography thin-layer chromatography (TLC). 178 
As shown in Figure 2a (left panel) there was a clear visual dose-dependent reduction 179 
in the production of α-MAMEs and k-MAMEs upon treatment with GSK3011724A. 180 
This characteristic profile of total MAMEs inhibition and FAMEs accumulation 181 
mirrors the known fatty acid synthase (FAS)-II inhibitors TLM and INH (Fig. 2a, 182 
middle panel). When spots were excised from the TLC and quantified by scintillation 183 
counting (Table 4), GSK3011724A at 4 x MIC in comparison to the non-treated 184 
control produced a 55.2 % and 42.3 % reduction in α-MAMEs and k-MAMEs, 185 
respectively. In contrast, quantification of the levels of FAMEs increased by 186.5 % 186 
at 4 x MIC. When compared to the known KasA inhibitor TLM, GSK3011724A at 1 187 
x MIC afforded a similar level of inhibition of α-MAMEs and k-MAMEs, and an 188 
increase in FAMEs synthesis, respectively (Table 4). A slightly less pronounced 189 
effect at their relative MICs was observed for INH in comparison to GSK3011724A 190 
(Table 4). The inhibition of mycolic acid biosynthesis by GSK3011724A was even 191 
more apparent when cell wall bound α- and k-MAMEs were analysed, with an almost 192 
visual complete inhibition in a dose-dependant manner, which was similar to INH and 193 
TLM (Fig. 2a, right panel). To investigate whether GSK3011724A affects the 194 
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synthesis of other mycobacterial lipids, addressing the potential of additional cell wall 195 
associated targets, the total cellular lipids (and fractionated apolar lipids and polar 196 
phospholipids) were extracted and analysed following drug treatment. Firstly, a 197 
decrease in trehalose dimycolate (TDM), trehalose monomycolate (TMM) and 198 
glycerol monomycolate (GroM) was observed with GSK3011724A (and TLM and 199 
INH), consistent with inhibition of mycolic acid biosynthesis (Fig. 2b, Table 4, and 200 
Supplementary Fig. 2a). Secondly, no significant differences were observed in lipid 201 
composition when apolar lipids and polar phospholipids were analysed by 202 
autoradiography-TLC (Supplementary Fig. 2a, b), suggesting that GSK3011724A 203 
does not target other lipid biosynthetic pathways, and is specific for KasA. 204 
 205 
To further corroborate that GSK3011724A inhibits mycolic acid biosynthesis and, 206 
more specifically, targets KasA, the impact on the MIC was investigated using strains 207 
of M. bovis BCG over-expressing components of FAS-II. The mycobacterial 208 
expression vectors, pMV261 containing M. tuberculosis kasA14, kasB14, fabH15, 209 
inhA16, hadABC17 and mabA16, were electroporated into M. bovis BCG and growth 210 
analysed at a concentration range with respect to the MIC of GSK3011724A (Fig. 211 
2c). M. bovis BCG containing the pMV261-empty vector exhibited no change in 212 
sensitivity to GSK3011724A compared to the wild-type untransformed strain, with an 213 
MIC of 0.5 µM (Fig. 2c). This was also apparent for the pMV261 constructs 214 
containing kasB, inhA, fabH, hadABC and mabA (Fig. 2c). However, ample growth of 215 
the KasA over-expressor strain was observed at 4 µM, indicating an increase in 216 
resistance, and a MIC shift of >8 x (Fig. 2c), providing further evidence to support 217 
KasA as the cellular target of GSK3011724A. 218 
 219 
   
 10 
Previous studies have reported KasA activity in an in vitro condensing assay using 220 
purified recombinant proteins18. This assay was replicated to demonstrate the specific 221 
inhibition of KasA by GSK3011724A. Initially, FabD was used to generate [14C]-222 
malonyl-AcpM from holo-AcpM and [14C]-malonyl-CoA. KasA, in the absence or 223 
presence of GSK3011724A, elongated C16-AcpM in a condensation reaction with 224 
[14C]-malonyl-AcpM. Treatment with 1 µM of GSK3011724A provided a 58.5% 225 
inhibition of KasA activity (based on triplicate data, Supplementary Fig. 3). 226 
 227 
To investigate whether GSK3011724A exerts its effect by directly binding to KasA, 228 
we employed a chemoproteomics strategy19,20. A tagged analogue (1) with an MIC of 229 
49 µM was generated, which was covalently linked to Sepharose beads (Fig. 3a). The 230 
tagged analogue-(1)-derivatised beads were incubated with M. bovis BCG extracts, in 231 
the absence or presence of an excess of unbound GSK3011724A. In this competition-232 
binding format, target proteins would be expected to bind to the beads predominantly 233 
in the absence of excess competing compound. After washing of the beads, bound 234 
proteins were digested with trypsin and subjected to quantitative mass spectrometry. 235 
Among more than 2,000 proteins identified, only three proteins were efficiently 236 
competed off the beads by excess GSK3011724A: KasA, and, to a lesser degree, the 237 
non-essential polyketide synthases Pks10 and Pks1121,22 (Fig. 3a, Supplementary 238 
Data 1 and 2). The experiment was repeated in a concentration-dependent format to 239 
determine half-maximal inhibition (IC50) values that refer to the concentration of 240 
compound (GSK3011724A) required to competitively block 50 % of the target (i.e. 241 
KasA) from binding to the beads (Fig. 3b, Supplementary Data 3 and 4). These IC50 242 
values are a measure of target affinity, but are also affected by the affinity of the 243 
target for the bead-immobilised ligand. The latter effect can be deduced by measuring 244 
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the depletion of the target proteins (KasA, Pks10 and Pks11) by the beads. Thus, 245 
apparent dissociation constants (Kdapp) can be determined, which are largely 246 
independent from the bead ligand19,23. The Kdapp value was determined as 9 nM for 247 
KasA, suggesting a high level of affinity for the enzyme. In excellent agreement with 248 
these chemoproteomic affinities, direct binding of GSK3011724A to purified KasA 249 
was also determined using Surface Plasmon Resonance (SPR) and found to be in the 250 
10-20 nM range (Supplementary Fig. 4). A much weaker apparent dissociation 251 
constant was observed for both Pks10 and Pks11 (Kdapp 1.4 µM). In addition, we 252 
compared the results of the active compound GSK3011724A with a structurally 253 
related inactive analogue 2 (MIC > 125 µM). The Kdapp for this inactive molecule was 254 
determined to be 4.5 µM for KasA, which corresponds to a ~490 fold window for 255 
KasA between active and inactive compound. There was no binding observed for 256 
Pks10 and Pks11 by the inactive analogue 2 (Fig. 3b, Supplementary Data 5).  257 
 258 
In order to evaluate the potential of GSK3011724A for interaction with human 259 
proteins, which could represent off-targets relevant for drug safety, we performed a 260 
similar set of chemoproteomics experiments with a human protein extract, generated 261 
by combining detergent (NP40) lysates from HEK293 cells, K562 cells and placenta 262 
tissue (Supplementary Data 6). Only a single protein showed moderate competition 263 
by GSK3011724A, NQO2, with an apparent dissociation constant of 4-6 µM. NQO2 264 
is an off-target of many small molecules drugs24. Other potential off-targets may exist 265 
that are not expressed in the cells and tissues used for the profiling, and the compound 266 
may exhibit binding modes, which are inconsistent with its immobilisation. However, 267 
taken together, the chemoproteomics data demonstrate that GSK3011724A is a highly 268 
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potent and selective inhibitor of KasA with no discernible off-targets in the above 269 
human cell lines and placenta tissue. 270 
 271 
Analysis of the KasA-GSK3011724A co-crystal structure 272 
 273 
Curious to understand the molecular details of GSK3011724A binding to KasA, a 274 
2.13 Å co-crystal structure of the dimeric KasA-GSK3011724A complex was solved 275 
(Table 5). All literature inhibitors to date, such as TLM, reside in the malonyl 276 
substrate pocket close to the catalytic Cys171 residue25,26 (Fig. 4a). However, 277 
computational docking studies to place GSK3011724A into this site produced 278 
puzzling binding modes, which did not explain the roles of the key molecular features 279 
of GSK3011724A. The co-crystal structure reveals that, in contrast to TLM, 280 
GSK3011724A uniquely binds within the large acyl channel that normally 281 
accommodates the growing meromycolic acid chain, unexpectedly trapping the open 282 
conformation of the enzyme (Fig. 4a). GSK3011724A sits at the branch point of the 283 
acyl channel, a feature thought to confer specificity for “kinked” unsaturated 284 
substrates. Within this site, density for a long linear molecule, modelled as 285 
polyethylene glycol (PEG), is also consistently present and perfectly complements the 286 
space between the compound and the protein (Fig. 4b). This sandwich of PEG and 287 
GSK3011724A enables the large acyl cavity to be filled, occupying the volume of the 288 
branched phospholipid chains previously observed within this pocket25.  289 
 290 
From the co-crystal structure, the structure-activity relationship of GSK3011724A is 291 
evident (Fig. 4b, c). The indazole ring lies across the flat hydrophobic surface formed 292 
by residues such as Gly200 and Pro201, and the amide of the sulfonamide makes a 293 
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key hydrogen bond with Glu199. This anchors the ligand in an ideal position, 294 
allowing the kink (introduced by the sulfonamide linkage) to place the butyl chain 295 
into an orthogonal narrow lipophilic channel lined by residues such as Ile347, Ile202 296 
and Phe239.  297 
 298 
The resistance-conferring mutations observed in Table 3 can be readily rationalised 299 
by the inhibitor binding site and MoA of GSK3011724A (Fig. 5a). Pro201 and 300 
Pro206 both lie within the acyl site and are in direct contact with the ligand (Fig. 5b). 301 
Exchange of proline for a hydrophilic serine residue (Pro201Ser) disfavours 302 
interactions with the aromatic indazole ring, whereas the Pro206Leu substitution 303 
introduces steric crowding of the ligand. The remaining mutations are found away 304 
from the inhibitor site, in regions likely to influence the conformational equilibrium 305 
and ease of transition between the closed and open state required for GSK3011724A 306 
inhibition. The α5 to α6 helix-turn-helix (HTH) arm of one KasA monomer, 307 
comprising of residues 115-145, must slide past its dimer counterpart (α'5-α'6) and 308 
the α'2 helix as the acyl cavity opens. Mutations Leu128Pro, Val137Ala, Met146Val 309 
and Leu205Pro are either within the HTH motif or the α2 helix and undergo 310 
substantial movement to the open form (Fig. 5c). Met277 also lies at the dimer 311 
interface, however, its position is fixed between the two states. This residue could be 312 
considered as the ‘ball’ in a ‘ball and socket’ joint around which the α5-α6 HTH 313 
pivots (Fig. 5d). Reducing the size of Met277 to valine may alter the movement and 314 
position of the HTH. Similarly, Thr114 sits at another fixed pivot point, the start of 315 
the first helix of the HTH (Fig. 5d). The positioning of Thr114 breaks the β-strand 316 
that proceeds it and anchors the HTH arm to its opposite β-strand partner Val198 via 317 
two hydrogen bonds (through a carbonyl-backbone interaction and by the interaction 318 
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of the threonine side chain hydroxyl to the carbonyl of Val198) (Fig. 5e). The 319 
Thr114Ser resistance conferring mutation would introduce more flexibility and may 320 
reduce the anchoring stability needed in this position.  321 
 322 
In summary, these crystallographic insights complete a consistent picture of the 323 
molecular MoA of this inhibitor and provide a platform for rational optimisation of 324 
the GSK3011724A scaffold as well as de novo structure-based drug design. 325 
Excitingly, this offers a fresh opportunity to target KasA at a site distinct from 326 
previous inhibitors and one that is able to achieve selectivity over other related β-327 
ketoacyl synthases (FabH and KasB) involved in fatty acid biosynthesis, as key 328 
residues required for affinity are not conserved (Fig. 5f, g). 329 
 330 
In vivo target engagement of GSK3011724A and KasA 331 
 332 
Although the evidence presented above provided a high level of confidence that KasA 333 
was the true biological target of GSK3011724A, there was still a need to confirm that 334 
target engagement was responsible for the potent in vivo activity. A selection of the 335 
M. tuberculosis spontaneous resistant mutants isolated against GSK3011724A were 336 
tested for their growth profile in mice using the acute model11 (Fig. 1d). While the 337 
two mutants showed an attenuated growth rate in untreated animals, their response to 338 
INH treatment remained essentially unchanged. Given the close relationship between 339 
KasA and InhA, the INH data were particularly significant, confirming that the 340 
observed resistance in vivo was not merely an artefact of the limited growth rate. In 341 
contrast with INH, the response with GSK3011724A against both strains with 342 
mutations mapping to kasA showed clear signs of resistance (Fig. 1d). Mutation 343 
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Met277Thr appeared to impart complete resistance up to the maximum dose tested 344 
(140 mg.kg-1), while mutation Pro201Ser gave a lesser response at 100 mg.kg-1. These 345 
results support the MIC shifts observed in vitro and furthermore provide a critical link 346 
between the target identification and in vivo validation of KasA. 347 
 348 
Discussion 349 
 350 
On-going efforts to combat drug-resistant TB have taken many forms including the 351 
re-purposing of broad spectrum antibacterials, target-based programs on 352 
mycobacterial enzymes, efforts to optimise or re-invent known TB drugs (like INH 353 
and RIF), and phenotypic screening approaches, which have all been widely 354 
reported4,27-32. In this work, through a variety of in vitro and in vivo experiments, a 355 
new chemical scaffold, exemplified by GSK3011724A, has been identified to 356 
specifically target an integral component of mycolic acid biosynthesis, KasA18. 357 
Mycolic acids are unique and fundamental components of the mycobacterial cell wall 358 
and KasA is essential in M. tuberculosis13.  359 
 360 
Mycolic acid biosynthesis involves two distinct fatty acid synthesis pathways. The 361 
FAS-I system is required for de novo fatty acid synthesis, where a single, 362 
multifunctional polypeptide generates short chain fatty acyl-CoA esters. FabH, a β-363 
ketoacyl ACP synthase, forms a pivotal link between FAS-I and FAS-II, condensing 364 
C14-CoA (generated by FAS-I) and malonyl-AcpM producing C16-AcpM15. This 365 
product is channelled to KasA of the FAS-II system33. The FAS-II system is 366 
comprised of four enzymes acting in a consecutive cycle: KasA and KasB, 367 
condensing enzymes18; MabA, a keto-reductase34; HadABC, a dehydratase35; and 368 
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InhA, an enoyl-reductase36. The FAS-II system enables fatty acid elongation leading 369 
to meromycolic acids (C56), which are then condensed with C26-CoA (from FAS-I) by 370 
the polyketide synthase Pks1337,38, followed by reduction, culminating in the 371 
production of mature mycolic acids39. The lipidomics experiments showing 372 
accumulation of FAMEs and depletion of MAMEs confirms that GSK3011724A 373 
specifically inhibits FAS-II and mycolic acid biosynthesis (Fig. 2a, b, Table 4 and 374 
Supplementary Fig. 2). 375 
 376 
Inhibitors of KasA have been reported in the literature14,40,41. Most notable among 377 
these is TLM, which is known to inhibit all three mycobacterial Kas enzymes: KasA, 378 
KasB, and FabH14,15. Interestingly, GSK3011724A, unlike TLM and other Kas-379 
inhibitors, whether against M. tuberculosis or other bacteria (via FabH, FabB and 380 
FabF), displayed unique specificity, targeting only KasA (Fig. 2c). An explanation of 381 
this finding comes from close inspection of the GSK3011724A-KasA complex crystal 382 
structure, where specific changes in the acyl pockets of the related enzymes disfavour 383 
the unique binding mode of GSK3011724A (Fig. 4 and 5). For example, the 384 
Gly200Arg and Pro201Thr changes from KasA to KasB no longer allow the indazole 385 
ring to sit favourably in the acyl pocket of KasB (Fig. 5f). This offers an explanation 386 
as to why the WGS data did not result in the identification of SNPs in KasB and why 387 
the resistance mutations in KasA often map to points of variation amongst the Kas 388 
enzymes. 389 
 390 
Importantly, GSK3011724A, despite representing an un-optimised screening hit, 391 
gives at least one order of magnitude greater potency relative to the most studied 392 
KasA inhibitor, TLM, and its favourable PK properties allowed for the critical in vivo 393 
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experiments described in this work. The data obtained from murine assays (both acute 394 
and chronic infection) exemplify the credible potential of KasA inhibitors to give 395 
significant efficacy and, to our knowledge, offer the first in vivo validation of KasA as 396 
a drug target (Fig. 1d). Together with the promising drug-like profile of 397 
GSK3011724A, these data provide significant confidence for the future exploration of 398 
KasA as a drug target, inhibitors of which could become key players in the 399 
development of new anti-tubercular drugs and will be explored in a future publication.  400 
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Materials and Methods 401 
 402 
Synthetic and characterisation details for the compounds and the SPR experiment 403 
described herein can be found in the Supplementary Methods. All animal studies 404 
were ethically reviewed and carried out in accordance with European Directive 405 
2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals. The 406 
human biological samples were sourced ethically and their research use was in 407 
accordance with the terms of informed consent. 408 
 409 
Assessment of acute and chronic efficacy in murine TB models 410 
 411 
INH was purchased from Sigma Aldrich and prepared freshly in distilled water. 412 
GSK3011724A was prepared freshly in 1 % aqueous methylcellulose. The assessment 413 
of the chronic and acute efficacy in murine TB models was performed using specific 414 
pathogen-free, 8-10 week-old female C57BL/6 mice purchased from Harlan 415 
Laboratories and allowed to acclimate for one week and kept under controlled 416 
conditions in a P3 high security facility with unlimited sterile food and water. 417 
 418 
In the acute model11, mice were intratracheally infected with M. tuberculosis H37Rv 419 
wild-type (H37Rv WT) 100,000 CFU for each mouse, and lungs harvested on day 9. 420 
GSK3011724A and INH were administered daily for 8 consecutive days, starting on 421 
day 1 after infection. In the chronic model42, mice (n = 2 mice at each dose level) 422 
were intratracheally infected with 100 CFU for each mouse; INH or GSK3011724A 423 
was administered daily for 8 consecutive weeks, starting 6 weeks after infection. 424 
Lungs were harvested 24 h after the last administration in both assays. All lung lobes 425 
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were aseptically removed, homogenised, and frozen. Homogenates were unfrozen and 426 
plated in 10 % OADC-7H11 medium supplemented with activated charcoal (0.4 %) 427 
and grown for 18-25 days at 37°C. Non-linear fitting was performed with the dose 428 
response data (logCFU versus dose) and the dose in mg.kg-1 that reduced lung 429 
bacterial burden by 99 % with respect to untreated mice was estimated (ED99). Mice 430 
were supervised every day under a protocol paying attention to weight loss, apparent 431 
good health (bristled hair and wounded skin) and behaviour (signs of aggressiveness 432 
or isolation). Animals were euthanised by CO2 inhalation.  433 
 434 
MIC determination and resistant mutant generation 435 
 436 
M. bovis BCG strain Pasteur and derivatives were cultured at 37°C and 5 % CO2 in 437 
static liquid or solid medium. Liquid medium contained Middlebrook 7H9 (Difco) 438 
supplemented with 0.05 % (v/v) Tween-80, 10 % (v/v) Middlebrook ADC and 0.25 % 439 
(v/v) glycerol.  Solid medium contained Middlebrook 7H11 agar (Difco) with 10 % 440 
(v/v) Middlebrook OADC and 0.5 % (v/v) glycerol. Where applicable, 25 µg.mL-1 441 
Kanamycin was added to the liquid or solid media to select for mycobacterial 442 
plasmids. The constructs pMV261, pMV261-Mt-kasA, pMV261-Mt-kasB, pMV261-443 
Mt-fabH, pMV261-Mt-inhA, pMV261-Mt-hadABC and pMV261-Mt-mabA were 444 
electroporated into M. bovis BCG14-17.  Wild-type M. bovis BCG electrocompetent 445 
cells were prepared by pelleting a mid-log culture and washing with decreasing 446 
volumes of ice-cold 10 % (v/v) glycerol.  The cells were incubated on ice with 1 µg 447 
plasmid DNA before being transferred to a 0.1 cm electrode-gap electroporation 448 
cuvette and subjected to a single pulse of 1.8 kV.  Cells were recovered in liquid 449 
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media overnight at 37°C and selected on solid medium containing the appropriate 450 
antibiotic. 451 
 452 
The MIC of GSK3011724A was determined by plating 104, 103, 102, and 101 cells 453 
from a mid-log culture of M. bovis BCG on solid medium containing increasing 454 
concentrations of compound in a dose response format.  The MIC was defined as the 455 
concentration of compound that caused complete inhibition of bacterial growth.  M. 456 
bovis BCG and M. tuberculosis spontaneous resistant mutants were generated by 457 
plating 108 cells from a mid-log phase culture on solid media containing either 5 x, 10 458 
x or 20 x MIC of GSK3011724A. Potentially resistant colonies were inoculated into 459 
liquid media, cultured to mid-log growth phase, and selected on solid media 460 
containing 5 x MIC of GSK3011724A to confirm phenotypic resistance. The MIC of 461 
the resistant M. tuberculosis mutant strains against GSK3011724A was determined 462 
either using the MABA resazurin assay43 or by serial dilution and agar plating.  463 
 464 
Sequencing of resistant mutants 465 
 466 
Wild-type M. bovis BCG and the M. bovis BCG GSK3011724A resistant mutants 467 
were characterised by WGS6,9. Briefly, purified genomic DNA was prepared for 468 
sequencing using the Nextera DNA Sample Preparation Kit (Illumina).  The DNA 469 
libraries were purified and quantified using Agencourt AMPure XP beads (Beckman 470 
Coulter Genomics) and Quant-iT PicoGreen dsDNA kit (Life Technologies), 471 
respectively.  Fragment sizes were determined using an Agilent Technologies 2100 472 
Bioanalyzer with a High Sensitivity DNA chip.  Following the MiSeq preparation 473 
guide, the libraries were sequenced on a MiSeq Benchtop Sequencer using the MiSeq 474 
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Reagent Kit v2, 300 cycles. Reads were aligned to the reference genome M. bovis 475 
BCG Pasteur 1173P2 (accession: NC_008769.1). 476 
 477 
The kasA gene (Rv2245) from M. tuberculosis GSK3011724A resistant mutants was 478 
sequenced specifically.  The gene was amplified by PCR using 0.5 µM of the flanking 479 
primers 5´- aggacaagtacggcgtcaag (forward) and 5´- gtaaccagctccgtcattg  (reverse). 480 
The amplification was performed with 0.02 U.µL-1 of KOD Xtreme™ Hot Start DNA 481 
Polymerase (Merck Millipore) and 0.4 mM each of dNTP. PCR conditions were: 2 482 
min at 94°C, followed by 30 cycles of 98°C for 10 s, 66°C for 60 s and 68°C for 10 s. 483 
The PCR product was purified from the band of a 0.8 % agarose gel (Seakem GTG 484 
Agarose, Lonza) with Illustra™ GFX™ PCR DNA and Gel Band Purification Kit, 485 
GE Healthcare.  The purified product was used for kasA automated sequencing (using 486 
the primers: Forward 1, cgaagattgagtcggagaac; Reverse 1, cttccatatcggtccgactc; 487 
Forward 2, gtcaagatcggcggtcac; Reverse 2, cagacttcggcgcgtaca; Forward 3, 488 
gtgatcggtctgcagcttg; Reverse 3, ctcctccgtctcgatgag; Forward 4, ctcatcgagacggaggag; 489 
Reverse 4, cgttgggcatgatcatctg; Forward 5, tgtacgcgccgaagtctg; Reverse 5, 490 
gatcccacttggtgacgaac). DNA sequencing reactions were performed with a BigDye 491 
terminator V3.1 cycle sequencing kit (Applied Biosystems, Inc.).  492 
 493 
Synthesis of FAMEs and MAMEs 494 
 495 
The whole cell effect of GSK3011724A was studied by treating M. bovis BCG 496 
cultures (10 mL) at an OD600nm of 0.4-0.6 with a dose dependent increase in drug for 497 
20 h before labelling using 1 µCi.mL-1 [1-14C]sodium acetate (37 MBq, PerkinElmer) 498 
for a further 24 h at 37°C . The total FAMEs and MAMEs were extracted14,44. Briefly, 499 
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cells were pelleted and incubated overnight in 2 mL of 5 % tetrabutylammonium 500 
hydroxide at 100°C. The following day, 4 mL of dichloromethane was added with 501 
300 µL of iodomethane and 2 mL of water and mixed for 30 min. The reaction was 502 
centrifuged and the upper aqueous layer discarded. Water (3 mL) was added to the 503 
lower organic layer, mixed and centrifuged as before and repeated once more. The 504 
organic layer was evaporated to dryness and the methyl esters re-dissolved in diethyl-505 
ether (4 mL) and transferred to a fresh tube. The diethyl-ether was evaporated and 200 506 
µL of dichloromethane used to re-dissolve the extracted methyl esters. The total 507 
FAMEs and MAMEs were analysed by TLC, using equal counts (cpm) and exposed 508 
to Kodak X-Omat film. Quantification of labelled FAMEs and MAMEs was 509 
determined by excising spots directly from the TLC plates and subjecting them to 510 
scintillation counting using 10 mL of EcoScintA. 511 
 512 
Extraction of cell wall bound MAMEs and lipids 513 
 514 
M. bovis BCG was drug-treated and labelled as described above.  The cell wall bound 515 
MAMEs, apolar and polar phospholipids were extracted and analysed44.  Briefly, the 516 
cell pellet was extracted 4 times using 4 mL of chloroform:methanol:water (10:10:3, 517 
v/v/v), retaining the delipidated cell pellet (for analysis of cell wall bound mycolic 518 
acids) and collecting the solvent extract sequentially, which was combined and dried. 519 
To the dried extract, 4 mL of chloroform:methanol:water (10:10:3, v/v/v) was added, 520 
followed by chloroform (1.75 mL) and water (0.75 mL), and the entire mixture 521 
centrifuged and the lower organic layer recovered. The lower organic layer was 522 
washed twice using chloroform:methanol:water (2 mL, 3:47:48, v/v/v) and dried to 523 
provide a total lipid extract, which was re-dissolved in chloroform:methanol (2:1, v/v) 524 
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and an aliquot subjected to scintillation counting using 10 mL of EcoScintA. The total 525 
lipid extract was further partitioned between the phases arising from methanol:0.3 % 526 
NaCl (2 mL, 100:10, v/v) and 2 mL of petroleum-ether (60-80oC). The entire contents 527 
were mixed on a blood rotor, centrifuged and the upper layer collected. The lower 528 
layer was re-extracted using 2 mL of petroleum ether (60-80oC). The combined 529 
petroleum-ether layers were evaporated to afford the crude apolar lipids. To the lower 530 
organic layer, 2.3 mL of chloroform:methanol:0.3 % NaCl (50:100:40, v/v/v) was 531 
added, followed by 750 µL of chloroform:methanol:0.3 % NaCl (50:100:40) and a 532 
further 1.3 mL of chloroform and 1.3 mL 0.3 % NaCl.  The entire contents were 533 
mixed, centrifuged and the lower layer recovered and dried to afford the crude polar 534 
lipids. The apolar and polar lipids were re-dissolved in chloroform:methanol (2:1, v/v) 535 
and an aliquot subjected to scintillation counting using 10 mL of EcoScintA.  The 536 
total lipid extracts and apolar/polar lipids were analysed by TLC in the following 537 
solvent systems using equal counts (as stated) before being exposed to Kodak X-538 
Omat film. Apolar lipids were resolved using three solvent systems A: first direction, 539 
petroleum-ether (60:80oC)):ethyl acetate (98:2, v/v, thrice); second direction,  540 
petroleum-ether (60:80oC):acetone (98:2, v/v). Solvent system B: first direction, 541 
petroleum-ether (60:80oC):acetone (92:8, v/v, thrice); second direction, 542 
toluene:acetone (95:5, v/v). Solvent system C: first direction, chloroform:methanol 543 
(96:4, v/v); second direction,  toluene: acetone (80:20, v/v). The polar lipids were 544 
analysed using chloroform:methanol:ammonium hydroxide:water (65:25:0.5:3.6, 545 
v/v/v). The total lipid extract was analysed using chloroform:methanol:concentrated 546 
ammonium hydroxide (80:20:2, v/v/v) to reveal TDM and TMM. The recovered 547 
delipidated cells were used to analyse cell wall bound mycolic acids following release 548 
using 5 % tetrabutylammonium hydroxide at 100°C and methylation as described 549 
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above for total FAMEs and MAMEs. The recovered cell wall bound MAMEs were 550 
analysed by TLC, using an equal aliquot (5 %) and exposed to Kodak X-Omat film. 551 
 552 
Original scans of all TLCs are shown in Supplementary Figure 5. 553 
 554 
KasA activity assay 555 
 556 
Recombinant FabD, holo-AcpM and C16-AcpM were over-expressed in C41 (DE3) E. 557 
coli cells from pET28a-fabD and pET28a-acpM and purified45. Briefly, cells were 558 
resuspended in buffer (50 mM potassium phosphate, pH 7.5, 0.5 M NaCl and 10 mM 559 
(AcpM) / 25 mM (FabD) imidazole) containing DNAse, Complete protease inhibitor-560 
cocktail tablets (Roche) and 0.1 mg.mL-1 lysozyme. Cells were disrupted by 6 passes 561 
through a French Press and the clarified lysate was loaded onto a pre-equilibrated 562 
(with buffer) Ni2+-charged 1 mL His-Trap column. A step gradient of imidazole (50-563 
1000 mM) was used to wash and elute the recombinant protein. Recombinant AcpM 564 
was dialysed into 0.1 M Tris pH 7.5, 500 mM NaCl and loaded onto a column 565 
containing 1 mL Thiopropyl-Sepharose 6B.  Acyl-AcpM was collected in the flow 566 
through.  Holo-AcpM was eluted with increasing concentration of β-mercaptoethanol 567 
(5-100 mM). All purified enzymes were dialysed firstly against 50 mM Tris pH 7.5, 568 
50 mM NaCl, 10 % (v/v) glycerol, 2 mM EDTA and secondly against the same buffer 569 
without EDTA.  570 
 571 
The E. coli expression plasmid, pET28a-kasA18, was transformed into E. coli BL21 572 
(DE3). A resulting single colony was used to inoculate an overnight culture, which 573 
was subsequently used to inoculate 1 L LB broth, 1 % (w/v) glucose, 50 µg.mL-1 574 
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Kanamycin.  The culture was incubated at 37°C, 180 rpm, until OD600nm reached 0.4-575 
0.6.  The culture was cooled to 16°C and induced with 1 mM IPTG.  Growth was 576 
continued for 20 h at 16°C, 180 rpm, and then the cells were harvested by 577 
centrifugation. The cell pellet was resuspended in buffer (50 mM potassium 578 
phosphate, pH 7.45, 0.5 M NaCl and 10 mM imidazole) containing DNAse, RNAse, 579 
Complete protease inhibitor-cocktail tablets (Roche) and 0.1 mg.mL-1 lysozyme.  580 
Cells were disrupted by 6 passes through a French Press at 1 ksi and centrifuged at 581 
15,000 rpm, 40 min at 4°C.  The supernatant was loaded onto a pre-equilibrated (with 582 
buffer) Ni2+-charged 1 mL His-Trap column. The column was washed extensively 583 
using buffer and the proteins were eluted with a step-wise gradient of imidazole (50, 584 
100, 150, 200, 350 and 500 mM).  SDS-PAGE was used to detect the presence of 585 
purified KasA, which was dialysed against 50 mM Tris.HCl, pH 7.5, 300 mM NaCl, 586 
10 % (v/v) glycerol and stored at -20°C.   587 
 588 
The assay for mycobacterial KasA activity was performed18. Assay components were 589 
mixed together in a batch fashion, before equally dividing according to the number of 590 
assays performed. The amounts stated correspond to a single reaction. Holo-AcpM 591 
(40 µg), in 200 mM potassium phosphate pH 7.0, 5 mM β-mercaptoethanol and a 592 
final volume of 40 µL, was incubated on ice for 30 min. [2-14C]Malonyl-CoA (0.05 593 
µCi, 1.85 kBq, PerkinElmer) and 50 ng FabD were added and the reaction was 594 
incubated at 37°C for 1 h. 42.5 µg C16-Acpm:Holo-AcpM mix (42.5 µg) was added 595 
with 200 mM potassium phosphate and 5 mM β-mercaptoethanol to a final volume of 596 
89 µL.  The reaction mix was aliquoted into 1.5 mL microcentrifuge tubes, according 597 
to single assay conditions. An aliquot of KasA (0.25 µg) (or replaced with an equal 598 
volume of buffer) was added and the reactions were incubated at 37°C for 1.5 h.  The 599 
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reaction was quenched with 2 mL of freshly prepared reducing solution: 5 mg.mL-1 600 
NaBH4 in 0.1 M K2HPO4, 0.4 M KCl, 30 % (v/v) tetrahydrofuran. The reaction was 601 
incubated overnight at 37°C. The reduced β-ketoacyl product was extracted twice 602 
using 2 mL of water-saturated toluene, and the combined organic phase washed thrice 603 
using 2 mL of toluene-saturated water.  The organic layer was transferred to a 604 
scintillation vial and dried. The radiolabelled product was quantified by liquid 605 
scintillation counting using 10 mL of EcoScintA. 606 
 607 
Chemoproteomics 608 
 609 
The chemoproteomic inhibition binding experiments were performed as previously 610 
described19,20.  Briefly, sepharose beads were derivatised with 1, the GSK3011724A-611 
tagged analogue, at 2 mM compound concentration. Beads were washed and 612 
equilibrated in lysis buffer (50 mM Tris-HCl, pH 7.4, 0.4 % Igepal-CA630, 1.5 mM 613 
MgCl2, 5 % glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na3VO4, 1 mM 614 
dithiothreitol (DTT), and one Complete EDTA-free protease inhibitor tablet (Roche)). 615 
The equilibrated beads were incubated at 4°C for 1 h either with 0.1 mL (0.3 mg) M. 616 
bovis BCG extract or with 1 mL (5 mg) mixed HEK293/K-562/Placenta extract, 617 
which was pre-incubated with compound or DMSO (vehicle control). Beads were 618 
transferred either to Filter plates (Durapore (PVDF membrane, Merck Millipore)) or 619 
to disposable columns (MoBiTec), washed extensively with lysis buffer and eluted 620 
with SDS sample buffer. Proteins were alkylated, separated on 4–12 % Bis-Tris 621 
NuPAGE (Life technologies) and stained with colloidal Coomassie. Gel lanes were 622 
cut into three slices and subjected to in-gel digest using LysC for 2 h and trypsin 623 
overnight19. Digestion, labelling with TMT isobaric mass tags, peptide fractionation, 624 
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and mass spectrometric analyses were performed19,46. Proteins were quantified by 625 
isobaric mass tagging and LC-MS/MS. The proteins.fasta file for M. bovis BCG was 626 
downloaded (May 11th 2011) from 627 
http://genome.tbdb.org/annotation/genome/tbdb/MultiDownloads.html and 628 
supplemented with the sequences of bovine serum albumin, porcine trypsin and 629 
mouse, rat, sheep and dog keratins. Decoy versions of all proteins were created and 630 
added. The search database contained a total of 11,492 protein sequences, 50 % 631 
forward, 50 % reverse. Protein identification and quantification was performed47. 632 
Proteins identified with >1 unique peptide matches were considered for further data 633 
analysis. Apparent dissociation constants were determined by taking into account the 634 
protein depletion by the beads19. Raw data tables for the chemoproteomics 635 
experiments can be found in the Supplementary Data 1-6. 636 
 637 
The M. bovis BCG extracts were prepared as follows: M .bovis BCG was cultured in 638 
7H9 medium without glycerol and supplemented with 2 % (w/v) glucose and 0.025 % 639 
(v/v) tyloxapol at 37°C for 8-10 days to reach an OD600nm of 0.8-1.0. The culture was 640 
centrifuged and the pellet was washed with PBS and 0.025 % (v/v) tyloxapol. The 641 
pellet was resuspended in lysis buffer (0.4 % (v/v) Igepal was replaced with 0.8 (v/v) 642 
% NP40) and sonicated for three cycles at 50 % amplitude for 30 s (Sonics-643 
VibracellTM) in ice. This lysate was ultracentrifuged at 4°C for 60 min and the 644 
cellular debris was discarded. 645 
 646 
KasA protein production and structure determination 647 
 648 
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The over-expression plasmid, pET28a-kasA, was transformed into E. coli BL21 649 
(DE3) cells. A single colony was used to inoculate 100 mL LB broth containing 50 650 
µg.mL-1 Kanamycin and 1 % (v/v) glucose.  Cells were cultured overnight at 30°C, 651 
240 rpm.  A 20 L Biolaffite fermenter containing 15 L of Overnight Express Instant 652 
TB (Merck), 1 % (v/v) glycerol, 50 µg.mL-1 Kanamycin, and 20 mL of antifoam 653 
(DC1520) was inoculated with the overnight culture to 2 % (v/v).  The culture was 654 
grown at 37°C, 340 rpm, 12 L.min-1 air flow.  The fermenter was cooled to 25°C 655 
when the OD600nm reached 2.4.  The culture was incubated for 20 h before harvesting 656 
the cells. The cell pellet was resuspended in 5 mL.g-1 cells in Buffer A (50 mM Tris, 657 
500 mM NaCl, 10 % (v/v) glycerol, 2 mM DTT, pH 8.5, with 1 mg.mL-1 lysozyme, 658 
Protease inhibitor cocktail set III (Sigma) and 10 μL Benzonase). The sample was 659 
lysed by sonication on ice for 10 min (10 s on, 10 s off).  The lysate was centrifuged 660 
at 18,000 rpm, 4°C for 30 min.  The supernatant was loaded onto a pre-equilibrated 661 
Ni2+-charged 10 mL His-Trap column. The column was washed back to baseline with 662 
Buffer A and the protein was eluted using a linear gradient over 20 column volumes 663 
using Buffer B (Buffer A containing 500 mM imidazole). KasA was further purified 664 
by gel filtration in Buffer A using a Superdex 200 column.  665 
 666 
KasA was co-crystallised with GSK3011724A using protein at 10.6 mg.mL-1 and 667 
ligand at a nominal concentration of 30 mM in 100 nL + 100 nL sitting drops at 20°C. 668 
The well solution was 8 % (w/w) isopropanol, 0.2 M NaCl, 10 mM TCEP. Crystals 669 
were cryoprotected using 30 % (v/v) glycerol prior to flash freezing in liquid nitrogen. 670 
Data from a single crystal was collected at the Diamond Synchrotron Radiation 671 
Facility (i04) and processed in P31 to 2.13 Å using XDS (within AUTOPROC [Global 672 
Phasing Limited])48 and AIMLESS49. A molecular replacement solution was 673 
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determined with a previously collected in house structure using Phaser50. The P31 cell 674 
(α=β=90˚, γ=120˚, a=b=77.338 Å, c=147.675 Å) has two molecules in the 675 
asymmetric unit that form a dimer. Model building and refinement of the KasA 676 
structures was carried out using alternating rounds of COOT51 for manual model 677 
building and REFMAC52 for maximum likelihood refinement via CCP453. As the data 678 
was merohedrally twinned, TWIN refinement within REFMAC was used, with the 679 
refined twin fraction being 39 %. A clear difference in density for GSK3011724A, 680 
and also for a PEG like molecule was present in both chains in the dimer. Whilst PEG 681 
was not explicitly added to the wells, this was present in adjacent crystallisation 682 
conditions and we believe there may be trace PEG present. Alternatively, the linear 683 
molecule may be residual lipid present in the protein, although apo-structures do not 684 
contain this lipid and the protein is crystallised in the closed conformation even in 685 
PEG conditions. A stereo diagram is displayed in Supplementary Figure 6. Statistics 686 
for the data collection and refined co-ordinates are given in Table 5.  687 
  688 
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Data availability 689 
 690 
The atomic coordinates and structure factors reported in this paper have been 691 
deposited in the Protein Data Bank with the code 5LD8. Data is available upon 692 
request from the corresponding authors. 693 
  694 
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Figure Legends 880 
 881 
Figure 1. The anti-tubercular activity of GSK3011724A. (a) Chemical structure of 882 
GSK3011724A. (b, c) GSK3011724A was evaluated in an acute (b) and chronic (c) 883 
model of murine TB infection. Each symbol represents data from a single mouse. A 884 
two-fold log CFU reduction equates to a 2 log CFU difference compared to untreated 885 
mice at the end of the treatment period. Untreated mice gave a log CFU count of 7.1 ± 886 
0.1 (mean ± SD, n=5 mice) in the acute assay and 5.8 ± 0.26 (mean ± SD, n= 7 mice 887 
for the INH experiment) or 6.0 ± 0.5 (mean ± SD, n= 5 mice for GSK3011724A 888 
experiment) in the chronic assay. (d) Comparison of the in vivo efficacy of 889 
GSK3011724A and INH against M. tuberculosis H37RV wild-type (H37RV WT) and 890 
M. tuberculosis KasA mutant strains. Mice were infected with each strain and 891 
administered with INH or GSK3011724A at different doses during the acute phase 892 
(days 1 to 8 after infection). Each dot represents data from a single mouse. Log CFU 893 
counts are shown as the difference with respect to the untreated group infected with 894 
each strain (∆logCFU for each mouse).  895 
 896 
  897 
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Figure 2. Inhibition of mycolic acid biosynthesis by GSK3011724A. (a) M. bovis 898 
BCG cultures, labelled with [14C]-acetate, were treated with GSK3011724A, TLM 899 
and INH. The total FAMEs and MAMEs were extracted and analysed by 900 
autoradiography-TLC using equal counts (25,000 cpm) for each lane, respectively 901 
(left and middle panels). In addition, cell wall bound MAMEs were isolated and an 902 
equal aliquot (5 %) was analysed by autoradiography-TLC for each lane, respectively 903 
(right panel). (b) M. bovis BCG total cellular lipids containing TDM/TMM were 904 
extracted following labelling and drug treatment (GSK3011724A, TLM and INH) and 905 
analysed by autoradiography-TLC using equal counts (25,000 cpm) for each lane, 906 
respectively. (c) Impact on the MIC of GSK3011724A upon the over-expression of 907 
members of FAS-II in M. bovis BCG. The over-expression constructs of M. 908 
tuberculosis enzymes (Mt) pMV261-Mt-kasA, pMV261-Mt-kasB, pMV261-Mt-fabH, 909 
pMV261-Mt-inhA, pMV261-Mt-hadABC and pMV261-Mt-mabA were electroporated 910 
into M. bovis BCG and the MIC of GSK3011724A was evaluated with reference to 911 
M. bovis BCG pMV261. The outer and inner spots represent 103 and 102 cells plated, 912 
respectively. 913 
 914 
 915 
  916 
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Figure 3. Chemoproteomics profiling of GSK3011724A. (a) A propylamine-tagged 917 
derivative of GSK3011724A (1, inset) was synthesised and covalently immobilised to 918 
NHS-activated sepharose. Beads were incubated with M. bovis BCG extract either in 919 
the presence of vehicle (DMSO) or GSK3011724A (10 µM, 40 µM). Proteins 920 
captured by the beads in both conditions were quantified by LC-MS/MS analysis. 921 
KasA, Pks10 and Pks11 were identified as potential targets of GSK3011724A by 922 
virtue of their reduced capturing in the presence of excess GSK3011724A. (b) 923 
Generation of IC50 values for KasA, Pks10 and Pks11. The chemoproteomic 924 
experiment was performed as in a but over a range of concentrations of the competing 925 
‘free’ inhibitor GSK3011724A (2 µM – 0.003 µM for KasA, 40 µM – 0.16 µM for 926 
Pks10 and Pks11) and a structurally related inactive analogue, 2 (40 µM – 0.16 µM).  927 
Apparent dissociation constants for GSK3011724A were determined from two 928 
independent experiments. 929 
 930 
  931 
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Figure 4. X-ray crystallographic analysis of KasA complexed with 932 
GSK3011724A. (a) Co-crystal structure of KasA dimer (yellow, blue) with 933 
GSK3011724A (green space filled) and PEG (green sticks) bound with the open 934 
conformation of the acyl channel. The active site cysteine C171 is shown in line 935 
format, as are an overlay of the TLM and a phospholipid ligand taken from PDB entry 936 
4C7225. (b) GSK3011724A and PEG both shown in stick format filling the acyl 937 
channel. (c) Hydrogen bonds between GSK3011724A and E199 within the binding 938 
site.  939 
  940 
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Figure 5. Impact of resistance-conferring mutations on the KasA-GSK3011724A 941 
crystal structure and structural comparison of KasA with KasB and FabH. (a) 942 
Mapping of residues where resistance mutations occur onto the dimeric KasA-943 
GSK3011724A X-ray crystallographic complex. GSK3011724A (green stick) marks 944 
the acyl channel, whereas TLM (magenta) from PDB entry 4C7225 marks the malonyl 945 
pocket.  (b) Residues P201 and P206 that confer resistance by direct interactions with 946 
GSK3011724A are shown, as are the proximity of other resistance positions visible. 947 
(c) A ribbon representation of the open and closed forms of KasA with resistance 948 
mutations highlighted. The open KasA-GSK3011724A dimer is shown in yellow and 949 
blue (chain A, B respectively).  The apo, closed conformation (PDB entry 2WGD26) 950 
is shown in orange and purple. The HTH arm formed by α5-α6 and the α'2 from its 951 
dimer partner move substantially on transition between the open and closed states. 952 
Residues within these two regions of movement where resistance mutations are found 953 
are shown in stick format. GSK3011724A, PEG and other residues sensitive to 954 
resistance mutations are shown in line format. (d)! Surface around Chain A within 955 
KasA-GSK3011724A complex shown to illustrate the role of M277 in the open and 956 
closed states. Colouring and representations identical to c. (e) Hydrogen bonding 957 
interactions around T114 within the open KasA-GSK3011724A complex. (f) 958 
Structural alignment of KasA-GSK3011724A (yellow and blue) with KasB (PDB 959 
entry 2GP654) (magenta). The indazole ring of GSK3011724A sits favourably over 960 
G200 and P201 in KasA. In KasB, the respective residues of T199 and R200 would 961 
not be able to accommodate this favourable binding mode. (g) Structural overlay of 962 
KasA-GSK3011724A (yellow and blue) with FabH (PDB entry 2QNZ55) (orange). In 963 
FabH, T145 would directly clash with the indazole ring of GSK3011724A, 964 
accounting for the compound selectivity for KasA.    965 
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Tables 966 
 967 
 968 
 969 
 970 
 971 
 972 
Table 1.  In vitro profile of GSK3011724A.  973 
 974 
 975 
 976 
  977 
Assay Value 
MIC H37Rv 0.8 µM 
HepG2 IC50 >100 µM 
ChromLogD7.4 3.8 
Kinetic Solubility >550 µM 
hERG IC50 >50 µM 
CYP3A4 IC50 >40 µM 
CYP1A2 IC50 >50 µM 
CYP2C9 IC50 12.6 µM 
CYP2D6 IC50 >50 µM 
18 Gram-positive and Gram-negative species  >128 µg.mL-1 
Plasma Protein Binding (mouse) 76.9% 
Plasma Protein Binding (human) 
Cli (mouse) 
91.8% 
6.1 mL.min-1g-1 
Cli (human) 0.95 mL.min-1g-1 
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 978 
 979 
 980 
Target 
Dose 
(mg.kg-1) 
Cmax 
(ng.mL-1) 
Cmax/Dose
ng.mL-1 
(mg.kg-1) 
tmax 
(h) 
AUC0-t 
(ng.h.mL-1) 
DNAUC 
ng.h.mL-1 
(mg.kg-1) 
10a 917±279 84.7±21.5 0.25-0.75 1099±152 104±19.1 
25 1392±424 63.9±19.4 0.5 2279±581 107±27.3 
50 12500±153 250±23.1 0.25-1.0 32549±3009 667±64.2 
100 10570±572 120±6.49 0.75-1.0 57179±7559 667±57.2 
200 33000±7017 165±35.1 2.0 251437±37054 1272±188 
aMean and SD values calculated from n = 3 mice. 981 
 982 
Table 2. In vivo pharmacokinetic profile of GSK3011724A. Pharmacokinetic 983 
parameters estimated for GSK3011724A after a single oral gavage administration to 984 
female C57BL/6J mice (n = 3) at different doses. Mice dosed above 400 mg.kg-1 were 985 
withdrawn after the second administration of GSK3011724A due to poor clinical 986 
status. Standard Deviation (SD) of the mean is also included. Cmax = maximum 987 
concentration measured; AUC = Area under the curve; DNAUC = Dose normalised 988 
area under the curve.  989 
  990 
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Organism Mutant 
Frequency 
of SNP 
Genome 
position of 
SNP 
Base 
change 
Amino acid 
substitution 
M. bovis BCG 
1 
75 % 
2.44 % 
2497100 
2497376 
aCc/aGc 
cCc/cTc 
T114S 
P206L 
2" 100 %" 2497142" cTg/cCg" L128P"
3" 100 %" 2497373" cTg/cCg" L205P"
4" 100 %" 2497376" cCc/cTc" P206L"
5" 100 %" 2497195" Atg/Gtg" M146V"
6" 100 %" 2497589" aTg/aCg" M277T"
M. tuberculosis 
1 - 2518524 gTg/gCg V137A 
2" -" 2518524" gTg/gYg" V137A/V"
3" -" 2518524" gTg/gCg" V137A"
4" -" 2518524" gTg/gCg" V137A"
5" -" 2518715" Ccc/Tcc" P201S"
6" -" 2518715" Ccc/Tcc" P201S"
7" -" 2518715" Ccc/Tcc P201S 
8" -" 2518715" Ccc/Tcc" P201S"
9" -" 2518943" Atg/Gtg" M277V"
10" -" 2518944" aTg/aCg" M277T"
11" -" 2519327" Ggc/Agc" G405S"
 991 
Table 3: Sequencing of spontaneous resistant mutants identifies SNPs in kasA.  992 
WGS and sequencing of kasA from GSK3011724A-resistant mutants of M. bovis 993 
BCG and M. tuberculosis, respectively, revealed kasA-specific mutations. For the 994 
WGS of M. bovis BCG mutants, the frequency of SNP is shown.  This corresponds to 995 
the percentage of SNP in the cell population from which the genomic DNA was 996 
extracted. The kasA SNP frequency in the M. tuberculosis mutants cannot be deduced 997 
due to the method of analysis used. The genomic location of the mutations is stated. 998 
The missense mutations are represented in codons, where the capital letter identifies 999 
the base change. The ‘Y’ indicates a mixed population of ‘C’ or ‘T’ bases.  The 1000 
resulting amino acid substitutions are listed. 1001 
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Inhibitor 
Inhibitor 
concentration 
(µM) 
FAMEs α-MAMEs k-MAMEs TDM TMM 
cpm 
% 
relative to 
control 
cpm 
% relative 
to control 
cpm 
% 
relative to 
control 
cpm 
% relative 
to control 
cpm 
% relative 
to control 
Control 0 9796 100 4029 100 7641 100 3149 100 1425 100 
GSK3011724A 
0.25 16207 165 3438 85 7147 94 -ND -ND -ND -ND 
0.5 17780 182 3026 75 6651 87 864 27 911 64 
1 16478 168 2488 62 4925 64 874 28 893 63 
2 18268 186 1806 45 4407 58 -ND -ND -ND -ND 
4 -ND -ND -ND -ND -ND -ND 652 21 951 67 
Control 0 10231 100 4156 100 6722 100 -* -* -* -* 
TLM 95 15334 150 2721 65 3727 55 817 26 704 49 
INH 1.5 16926 165 1426 34 1808 27 642 20 552 39 
Table 4:  Quantification of inhibition of mycolate containing products by GSK3011724A. Quantification of [14C]-labelled products were 1002 
determined by excising spots directly from TLC plates (Fig. 2a, left and middle panels, and Fig. 2b) and subjecting them to scintillation 1003 
counting using 10 mL of EcoScintA. *Control values as reported above; ND, not determined. 1004 
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X-ray diffraction data KasA / GSK3011724A 
Data collection  
Space group P31 
Cell dimensions  
    a, b, c (Å) 77.34, 77.34, 147.68 
    α, β, γ  (°)  90.000, 90.000, 120.000 
Resolution (Å) 66.98-2.13(2.38-2.13) 
Rmerge 0.053 (0.474) 
ccI1/2 0.998 (0.822) 
I/σI 16.9 (3.0) 
Completeness (%) 98.6 (97.3)  
Redundancy 4.3(4.0) 
Wilson B-factor 34.16 
  
Refinement  
Resolution (Å) 66.98-2.13 
No. reflections 235866 (60834) 
No. uniq reflections 54699 (15385) 
Rwork/ Rfree 0.162/0.186 
No. atoms 6470 
    Protein 6041 
    Ligand/ion 36/28 
    Water 365 
B-factors  
    Protein 39.70 
    Ligand/ion 39.90/48.61 
    Water 43.92 
R.m.s deviations  
    Bond lengths (Å)  0.0044 
    Bond angles (º) 0.8045 
Twin fraction 0.39 
 1005 
Table 5: Data collection and refinement statistics. Values in parentheses are for the 1006 
highest-resolution shell. Collection based on a single crystal. 1007 
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Supplementary Figure 1: In vitro death curve analysis of GSK3011724A.  M. 
tuberculosis was treated with GSK3011724A at 0.5 µM (10 x MIC in liquid media), 
along with the bacteriostatic and bactericidal compounds, linezolid (17.8 µM) and 
moxifloxacin (1.5 µM), respectively (10 x MIC), and compared to untreated cells 
(control).  CFU counts were performed in triplicate and analysed and displayed as 
mean ± standard deviation.  GSK3011724A exhibited bacteriostatic activity in this in 
vitro system, despite its bactericidal activity in vivo.  
 
 
  
  
 
 Supplementary Figure 2: Analysis of apolar and polar phospholipids from 
GSK3011724A-treated M. bovis BCG.  (a) M. bovis BCG cultures were treated with 
GSK3011724A, TLM and INH and labelled with [14C]-acetate. Drug concentrations 
are displayed (µM). The total lipid extract was recovered and further solvent 
partitioned giving rise to apolar and polar phospholipids, which were analysed by 
autoradiography-TLC (10,000 cpm, equal counts).  (a) 2D apolar lipid profiles using 
solvent systems A-C. (b) 1D polar phospholipid profile of polar phospholipids. 
PDIMs, phthiocerol dimycocerosates; TAG, triacylglycerol; MAT, multi-acylated 
trehaloses; F, fatty acids; GroM, monomycolylglycerol; PGL, phenolic glycolipid; 
PE, phosphatidylethanolamine; CL, cardiolipin; AC2PIM2, diacyl phosphatidylinositol 
dimannoside; PI, phosphatidylinositol; AC1PIM2, acyl phosphatidylinositol 
dimannoside. 
 
  
  
 
 
 
Supplementary Figure 3: Inhibition of KasA-mediated condensation activity by 
GSK3011724A.  KasA activity was monitored by the elongation of C16-AcpM using 
[14C]-malonyl-AcpM, which had been generated by the translocase reaction of FabD 
on holo-AcpM and [14C]-malonyl-CoA.  The condensation activity of KasA (0.25 µg) 
was assayed for 1.5 h in 0.1 % (v/v) DMSO with and without GSK3011724A (1 µM).  
In the absence of KasA, the enzyme was replaced by an equivalent volume of buffer.  
The results are based on the mean of triplicate reactions, with error bars representing 
the standard error. 
  
  
 
 
Supplementary Figure 4: Surface Plasmon Resonance binding studies of KasA 
and GSK3011724A.  Purified KasA was immobilised to a chip surface, and the 
binding of GSK3011724A was monitored. (a) Normalised signal from 
GSK3011724A titrations over immobilised KasA. The results are the mean of 
triplicate reactions, with error bars representing the standard error. (b) Representative 
sensorgrams of GSK3011724A titrations over immobilised KasA.  Kinetic fits are 
shown. 
 
  
  
 
Supplementary Figure 5: Original scans for all TLC data. 
 
  
  
 
Supplementary Figure 6: Stereo diagram of KasA complexed with 
GSK3011724A. (a) Fo-Fc density map for the ligand (contour level + 1.0 σ (blue)). 
(b) Fo-Fc density map for the ligand (contour level +/- 3.0 σ (blue/pink)).  
 
  
 Supplementary Table 
Assay Mode pXC50 
α1 nicotinic AChR Opener <4.3 (2) 
α1 nicotinic AChR Blocker <4.3 (2) 
Acetylcholinesterase Inhibition <4 (2) 
Adenosine A2a Agonist <4 (2) 
Adrenergic α1B Antagonist <4.6 (2) 
Adrenergic α2C Agonist <4 (2) 
Adrenergic β2 Agonist <4 (2) 
Adrenergic β2 Antagonist <4 (2) 
AhR Agonist <4 (2) 
Aurora B (STK12) Antagonist =5.1 (2) 
Cannabinoid CB2 Agonist <4 (2) 
COX-2 Blocker <4 (2) 
Dopamine D1 Antagonist <4 (2) 
Dopamine D2 Agonist <4 (2) 
Dopamine D2 Antagonist <4 (2) 
hERG Ion Works Antagonist <4.2 (3) 
Histamine H1 Antagonist <4.6 (2) 
KCNQ1/minK Blocker <4.6 (2) 
Kv1.5 Blocker <4.3 (1) 
LCK Antagonist <4.5 (2) 
L-type Ca channel (CaV1.2) Blocker <4 (2) 
Muscarine M1 Agonist <4.3 (2) 
Muscarine M1 Antagonist <4.3 (2) 
Muscarine M2 Agonist <4.3 (2) 
Muscarine M2 Antagonist <4.3 (2) 
NaV1.5 Blocker <4 (2) 
Neurokinin NK1 Antagonist <4.6 (2) 
NMDA Channel (NR2B) Blocker <4.3 (2) 
Norepinephrine Antagonist <4 (2) 
OATP1B1 Inhibition <4.3 (2) 
Opioid µ Agonist <4 (2) 
Opioid κ Agonist <4 (2) 
PDE3A Inhibition <4 (2) 
PI3Kγ Antagonist <4.5 (1) 
PXR Agonist <4.3 (2) 
Serotonin 5HT1B Agonist <4 (2) 
Serotonin 5HT1B Antagonist <4 (2) 
Serotonin 5HT2A Agonist <4.6 (2) 
Serotonin 5HT2A Antagonist <4.6 (2) 
Serotonin 5HT2C Agonist <4.6 (2) 
Serotonin 5HT2C Antagonist <4.6 (2) 
Serotonin 5HT3 Opener <4.3 (2) 
Serotonin 5HT3 Blocker <4.3 (2) 
Vasopressin V1a Antagonist <4.3 (2) 
 
Supplementary Table 1: Off-target selectivity data for GSK3011724A.  
 Supplementary Methods 
 
Synthesis and characterisation of compounds 
 
 
Scheme 1: Synthesis of hit compound GSK3011724A 
 
The synthesis of GSK3011724A was performed as follows.  Analine 7 (929 mg, 6.31 
mmol) was dissolved in dichloromethane (20 mL), and the solution was cooled to 
0°C. Triethyl amine (2.64 mL, 18.94 mmol, 3 Eq.) was added followed by the 
sulfonyl chloride (1.95 mL, 15.78 mmol, 2.5 Eq.) over about 5 min, and then the 
mixture was allowed to warm to room temperate. After stirring for 3 h, complete 
consumption of the starting material was observed by LCMS. Methanol (20 mL) and 
2 N aqueous sodium hydroxide (12.6 mL, 25.2 mmol, 4 Eq.) were then added to 
hydrolyse the bis-sulfonamide to the desired mono-sulfonamide, and stirred for 22 h 
at room temperature.  The solution was concentrated to dryness, and the resulting 
mixture was diluted with dichloromethane and ammonium chloride. The aqueous 
layer was separated and extracted with dichloromethane, and the combined organic 
layers were dried over sodium sulfate. The resulting crude mixture was purified first 
by flash column chromatography (40 g cartridge) eluting with a 0-40 % iPrOH:cHex 
gradient. After concentration, the resulting coloured solid was re-crystallised from 
toluene to afford the desired product N-(1-methyl-1H-indazol-6-yl)butane-1-
sulfonamide (GSK3011724A) as a white solid (1.004 g, 3.57 mmol, 57 %). mp: 
 120.6–122.2°C. 1H NMR (400 MHz, CDCl3) δ 7.95 (1H, s), 7.68 (1H, d, J = 8.6 Hz), 
7.40 (1H, s), 7.15 (1H, s), 7.10 (1H, bs), 6.88 (1H, dt, J = 8.6, 1.5), 4.06 (3H, s), 3.13 
(2H, m), 1.83 (2H, m), 1.42 (2H, m), 0.91 (3H, t, J = 7.3 Hz). 13C NMR (100 MHz, 
DMSO-d6) δ ppm: 140.4, 137.3, 132.7, 122.2, 120.7, 115.0, 98.8, 50.6, 35.75, 25.6, 
21.1, 13.9. LCMS (ES) [M]+H calculated for C12H17N3O2S as 268.1120, found 268.1. 
 
 Scheme 2: Synthesis of linkable compound 1 
 
The synthesis of 1 was performed in a four-step reaction as follows: 6-nitro-1H-
indazole (3; 203 mg, 1.24 mmol) was dissolved in dry N,N-Dimethylformamide 
(DMF) (4.1 mL). It was treated successively with caesium carbonate (1216 mg, 3.73 
mmol, 3.0 Eq.) and tert-butyl (3-bromopropyl)carbamate (593 mg, 2.49 mmol, 2.0 
Eq.). After 16 h the reaction was diluted with ethyl acetate, transferred to a separatory 
funnel, washed with brine solution 3 x, and the organic layer was dried with 
anhydrous sodium sulfate, filtered, and concentrated. The crude reaction mixture was 
purified using a 12 g silica column (30 mL.min-1) on an Isco Brand auto column and 
was eluted with 40 % EtOAc/Hexanes to afford the desired product, tert-butyl (3-(6-
 nitro-1H-indazol-1-yl)propyl)carbamate (4) in 41.7 % yield. 1H NMR (400 MHz, 
CDCl3) δ 8.41 (1H, s), 8.15 (1H, s), 8.05 (1H, d, J = 8.8 Hz), 7.86 (1H, d, J = 8.8 Hz), 
4.78 (1H, br s), 4.57 (2H, t), 3.17 (2H, m), 2.19 (2H, m), 1.45 (9H, s); LCMS (ES) 
[M]+ calculated for C15H20N4O4 320.1485, found 321.3 at 0.92 min. 
 
Tert-butyl (3-(6-nitro-1H-indazol-1-yl)propyl)carbamate (58.9 mg, 0.184 mmol) was 
dissolved in Methanol (1.2 mL) and Tetrahydrofuran (THF) (0.61 mL) and then 
palladium on carbon (10 %) (11.74 mg, 0.110 mmol) was added. The atmosphere in 
the reaction flask was removed and replaced by hydrogen gas until the starting 
material had been consumed (2 h). The crude mixture was filtered through Celite, 
eluting with EtOAc, dried with anhydrous sodium sulfate and concentrated to afford 
the desired product, tert-butyl (3-(6-amino-1H-indazol-1-yl)propyl)carbamate (5) 
(51.6 mg, 0.178 mmol, 97 % yield), without further purification. 1H NMR (400 MHz, 
CDCl3) δ 7.81 (1H, s), 7.49 (1H, d, J = 8.3), 6.57 (1H, d, J = 8.5 Hz), 6.54 (1H, s), 
4.85 (1H, br s), 4.32 (2H, t), 3.88 (2H, s br), 3.07 (2H, m), 2.05 (2H, s), 1.43 (9H, s); 
LCMS (ES) [M]+ calculated for C15H22N4O2 290.1743, found 291.3 at 0.53 min. 
 
Tert-butyl (3-(6-amino-1H-indazol-1-yl)propyl)carbamate (51.6 mg, 0.178 mmol) 
was dissolved in Pyridine (0.854 mL) and was cooled to 0ºC with an ice bath. Butane-
1-sulfonyl chloride (35 µL, 0.270 mmol, 1.5 Eq.) was added drop wise. The mixture 
was stirred at 0°C and then allowed to reach room temperature. After 2 h, the reaction 
was quenched by addition of water and extracted with EtOAc, dried with MgSO4 and 
solvent removed. The crude reaction mixture was diluted in EtOAc, washed 
subsequently with 1.0 N HCl and then brine and the organic solvent was removed in 
vacuo. The crude reaction mixture was dissolved on silica and tert-butyl (3-(6-
 (butylsulfonamido)-1H-indazol-1-yl)propyl)carbamate (6) was purified using a 4 g 
silica column (18 mL.min-1) on an Isco Brand auto column, eluted with (30 %) 
EtOAc/Hexanes. 1H NMR (400 MHz, CDCl3) δ 7.96 (1H, s), 7.68 (1H, d, J = 8.5), 
7.42 (1H, s), 7.19 (1H, s), 6.97 (1H, br s), 4.88 (1H, s br), 4.44 (2H, t), 3.12 (4H, m), 
2.05 (2H, m), 1.84 (2H, m), 1.44 (11H, m), 0.91 (3H, t); LCMS (ES) [M]+ calculated 
for C19H30N4O4S 410.1988, found 411.4 at 0.83 min. 
 
Tert-butyl (3-(6-(butylsulfonamido)-1H-indazol-1-yl)propyl)carbamate (47.6 mg, 
0.116 mmol) was dissolved in DCM (1.739 mL), and Trifluoroacetic acid (TFA) 
(0.580 mL) was added and stirred for 1 h at room temperature. The reaction was 
condensed to dryness and the resulting oil was dissolved in MeOH and loaded onto an 
Isolute SCX column. The material was washed with MeOH and then the desired 
compound was eluted off of the column using 7.0 N Ammonia in MeOH. The solvent 
was removed to afford the desired product, N-(1-(3-aminopropyl)-1H-indazol-6-
yl)butane-1-sulfonamide (1) (34.3 mg, 0.110 mmol, 95 % yield), as an oil. 1H NMR 
(400 MHz, CDCl3) δ 7.96 (1H, s), 7.67 (1H, d, J = 8.5), 7.45 (1H, s), 6.92 (1H, d, 
J=8.5), 4.48 (2H, m), 3.26 (3H, s br), 3.13 (2H, m), 2.72 (2H, m), 2.06 (2H, m), 1.83 
(2H, m), 1.42 (2H, m), 0.90 (3H, t); LCMS (ES) [M]+ calculated for C14H22N4O2S 
310.1463, found 311.3 at 0.42 min. 
 
 
Scheme 3: Synthesis of inactive compound 2 
 
 The synthesis of 2 was performed as follows. GSK3011724A (110 mg, 0.411 mmol) 
was dissolved in N,N-dimethylformamide (10 mL), and the solution was cooled to 
0°C. Potassium carbonate (171 mg, 1.234 mmol, 3 Eq.) was added followed by 
iodomethane (100 µL, 1.606 mmol, 4.0 Eq.), and then the mixture was allowed to 
warm to room temperate and left stirring overnight. The reaction was diluted with 
water and ethyl acetate.  The organic phase was washed several times with aqueous 
ammonium chloride, dried over sodium sulfate, and concentrated under reduced 
pressure. The resulting crude mixture was purified first by flash column 
chromatography (4 g cartridge) eluting with a 0-40 % EtOAc:cHex gradient and 
concentrated under reduced pressure to afford the desired product N-methyl-N-(1-
methyl-1H-indazol-6-yl)butane-1-sulfonamide (2) as a white solid (92.5 mg, 0.329 
mmol, 80 %). 1H NMR (400 MHz, CDCl3) δ 7.98 (1H, s), 7.73 (1H, d, J = 8.6 Hz), 
7.49 (1H, s), 7.15 (1H, s), 7.14 (1H, dd, J = 8.6, 1.8), 4.07 (3H, s), 3.43 (3H, s), 3.02 
(2H, m), 1.83 (2H, m), 1.43 (2H, m), 0.93 (3H, t, J = 7.3 Hz). LCMS (ES) [M]+H 
calculated for C13H19N3O2S as 282.1276, found 282.1. 
 
Surface Plasmon Resonance studies 
 
Surface Plasmon Resonance (SPR) binding studies were performed using a Biacore 
T200 instrument (GE Healthcare) and a NiHC1000m chip (XanTec bioanalytics 
GmbH, Dusseldorf).  Chip preparation and binding analyses were performed at 25°C, 
with 10 mM HEPES pH 7.4, 150 mM NaCl, 200 µM TCEP, 0.005 % Tween 20, 1 % 
DMSO as running buffer.  After chip conditioning (120 s injection of 0.5 M EDTA, 
60 s injection of 500 µM NiCl2, both at 10 µl.min-1), KasA was captured by flowing 
protein (50 µg.ml-1 in running buffer) over sample flow-cells for 5-7 min, capturing 
 10,000 – 15,000 resonance units (RU) of protein.  Flow-cell 1 remained unmodified 
and was used as the reference channel.  Binding analyses for GSK3011724A were 
performed at 30 µl.min-1, using 120 s sample injection times with 1,800 s dissociation.  
GSK3011724A was diluted to 1 µM in running buffer, then serially diluted 7 times in 
3-fold steps, and samples were injected starting with the most dilute.  Analyses were 
repeated on the same surface.  Initial dose-responses were discarded due to baseline 
decay. Only data from matured KasA surfaces, where there was a suitable baseline, 
were analysed.  For each dose-response data set, responses at the end of the 
association phase were normalised to 0-100%, then combined with replicates and the 
data fitted with a 1:1 binding model. 
 
In vitro death curve assay 
 
M. tuberculosis H37Rv was cultured at 37oC to OD600nm 0.1-0.8 in Middlebrook 7H9 
broth supplemented with Middlebrook ADC and 0.025 % (v/v) tyloxapol. The culture 
was diluted to 5 x 105 CFU.ml-1 (10 mL). Cells were treated with 10 x MIC of the 
following drugs: GSK3011724A (5 µM), moxifloxacin (1.5 µM), linezolid (17.8 µM).  
A no drug control for positive growth was also included.  Cultures were grown in 
triplicate. A 100 µL aliquot was sampled at 0, 2, 4, 7 and 14 days and the cells were 
plated onto Middlebrook 7H10 solid media supplemented with Middlebrook OADC. 
Dilutions corresponding to 10, 100 and 1000 CFU were performed in PBS containing 
0.025 % (v/v) tyloxapol, and were plated in triplicate.  
 
